After a year of historic profits in 2021 following the mass roll-out of COVID-19 vaccines and related treatments, big pharma companies armed with cash for deals have been shifting their attention -
Overall, pharma, medical...more
2/3/2023
/ Acquisitions ,
Biotechnology ,
Coronavirus/COVID-19 ,
Global Dealmaking ,
Healthcare ,
Investment ,
Investors ,
Life Sciences ,
Mergers ,
Pharmaceutical Industry ,
Prescription Drugs ,
Vaccinations
Dealmakers in almost every industry had an outstandingly busy 2021. With just a few exceptions, the M&A boom swept across the US economy with deal values, in particular, up significantly on 2020 totals.
Nevertheless,...more
2/18/2022
/ Acquisitions ,
Biotechnology ,
Capital Markets ,
Domestic Dealmaking ,
Energy Sector ,
Financial Services Industry ,
Healthcare ,
Investment ,
Investors ,
Mergers ,
Pharmaceutical Industry ,
Retail Market ,
Technology Sector
Global dealmaking was consistently strong in 2021, with the value topping US$1 trillion in each quarter for the first time on record. This achievement is particularly impressive given the tumultuous deal environment, as M&A...more
Heightened interest in medical suppliers, contract research organizations and biotech firms resulted in an impressive year for healthcare dealmaking-
Dealmaking within the pharma, medical and biotech sector continued from...more
12/21/2021
/ Acquisitions ,
Biotechnology ,
Coronavirus/COVID-19 ,
Domestic Dealmaking ,
Healthcare ,
Investment ,
Investors ,
Life Sciences ,
Medical Research ,
Mergers ,
Special Purpose Acquisition Companies (SPACs) ,
Technology